Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: a review of the literature

Table 1 Summary of the epicutaneous immunotherapy (EPIT) aeroallergen clinical trials

References	Study population	Single-patch allergen dose	Cumulative-patch allergen dose	Skin preparation methods	Patch application time (h)	Primary outcomes	Secondary outcomes	Results with statistical and/or clinical significance: placebo vs. verum
Proof of concept trial: Senti et al. [13]	37 people	21 μg	252 μg	Tape-stripping	48	NPT	SS MS AEs	SS AEs
Efficacy trial: Agostinis et al. [17]	30 children	11.25 μg	135 μg	Idratation	24	SPT SS MS	None	SS MS
Dose-ranging trial: Senti et al. [18]	132 people	3 μg 15 μg 30 μg	18 μg 90 μg 180 μg	Tape-stripping	8	SS	wSS MS CPT SPT	SS^a wSS^b
Immune-response trial: Senti et al. [15]	98 people	21 μg	126 μg	Tape-stripping Abrasion	8	SS	MS CPT IgG4 IgE	SS IgG4^c

All the EPIT clinical studies were performed with Phl p 5
NPT nasal provocation test, SS symptoms score, MS rescue medication score, AEs adverse events, SPT skin prick test, wSS weekly recorded symptoms, CPT conjunctival provocatin test
^aPlacebo vs. high-dose verum group in the follow-up period
^bPlacebo vs. high-dose verum group both in the treatment period and in the follow-up period
^cPlacebo vs. treated group in the treatment period

ISSN: 1479-5876